Developing drugs to treat osteoporosis: Lessons learned?

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 5, 2010, Pages 867-869

  De Paula, Francisco J A ^a   Rosen, Clifford J ^a  

^a Maine Medical Center Research Institute   (United States)

Author keywords

Arzoxifene; Bone mineral density; Osteoporosis; SERMs

Indexed keywords

ARZOXIFENE; TAMOXIFEN;

BONE ATROPHY; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG SAFETY; DRUG TREATMENT FAILURE; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; MYCOSIS; NOTE; OSTEOPOROSIS; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; SECONDARY OSTEOPOROSIS; TREATMENT OUTCOME; VAGINITIS;

EID: 77949437412     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903575662     Document Type: Note

References (10)

1. Bolognese M, Krege JH, Utian WH, et al. Effects of arzoxiene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass. J Endocrinol Metab 2009;94:2284-2289
2. Seeman E, Crans GG, Diez-Perez A, et al. Anti-vertebral fracture efficacy of raloxifene: a metaanalysis. Osteoporos Int 2006;17:313-316
3. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741
4. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137
5. Martino S, Cauley JA, Barret-Connor E, et al. Invasive breast cancer risk reduction in postmenopausal women with osteoporosis treated with raloxifen for 8 years: results from the Continuing Outcomes Relevant to Evista Trial. J Natl Cancer Inst 2004;96:1751-1761
6. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of randomized, double-blind and active-controlled study. J Bone Miner Res 2008;23:525-535
7. Cummings SR, Eastell R, Ensrud K, et al. The effect of lasofoxifene on fractures and breast cancer: 3-years results from the PEARL Trial. J Bone Miner Res 2008;23:S81
8. Deshmane V, Krishnamurthy S, Melemed AS, et al. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol 2007;25:4967-4973
9. Sato M, Turner CH, Wang T, et al. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 1998;287:1-7
10. Ma YL, Bryant HU, Zeng Q, et al. Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J Bone Miner Res 2002;17:2256-2264